

Citations des publications de l'ACRC

(Dernière révision : 2017-04-28)

Rapports sur les investissements de
l'ACRC

Articles de revue

- 1) Almatar, A. et coll. (2014). Practice patterns and perceptions of survivorship care in Canadian genitourinary oncology: A multidisciplinary perspective. *Canadian Urological Association Journal*, 8(11-12), 409-17.
- 2) Barr, R. D. (2011). Adolescents, young adults, and cancer—the international challenge. *Cancer*, 117(S10), 2245-9.
- 3) Bender, J. L. et coll. (2012). Fostering partnerships in survivorship care: report of the 2011 Canadian genitourinary cancer survivorship conference. *Journal of Cancer Survivorship*, 6(3), 296-304.
- 4) Bender, J. L. et coll. (2013). A lot of action, but not in the right direction: Systematic review and content analysis of smartphone applications for the prevention, detection, and management of cancer. *Journal of Medical Internet Research*, 15(12), e287.
- 5) Boormans, J. L. et Zwarthoff, E. C. (2016). Limited funds for bladder cancer research and what can we do about it. *Bladder Cancer*, 2(1), 49-51.
- 6) Branton, P.E. (2008). Does Canadian research investment relate to cancer burden? *The Lancet Oncology*, 9(2):82-3.
- 7) Campbell, D. et coll. (2010). Bibliometrics as a performance measurement tool for research evaluation: The case of research funded by the National Cancer Institute of Canada. *American Journal of Evaluation*, 31(1), 66-83.
- 8) Carter, A. Jr. et Nguyen, C. N. (2012). A comparison of cancer burden and research spending reveals discrepancies in the distribution of research funding. *BMC Public Health*, 12(526). Repéré à <http://www.biomedcentral.com/1471-2458/12/526>
- 9) Carter, A. Jr., Delarosa, B. et Hur, H. (2015). An analysis of discrepancies between United Kingdom cancer research funding and societal burden and a comparison to previous and United States value. *Health Research Policy and Systems*, 13(62). Repéré à <http://health-policy-systems.biomedcentral.com/articles/10.1186/s12961-015-0050-7>
- 10) Carter, H. E., Schofield, D. J. et Shrestha, R. (2016). The productivity costs of premature mortality due to cancer in Australia: Evidence from a microsimulation model. *PloS ONE*, 11(12), e0167521.
- 11) Castillo-Pelayo, T. et coll. (2015). The importance of biobanking in cancer research. *Biopreservation and Biobanking*, 13(3), 172-7.
- 12) de Oliveira, C. et coll. (2013). Understanding the costs of cancer care before and after diagnosis for the 21 most common cancers in Ontario: A population-based descriptive study. *CMAJ Open*, 1(1), E1-E8.
- 13) Eckhouse, S. et coll. (2008). Trends in the global funding and activity of cancer research. *Molecular Oncology*, 2(1), 20-32.
- 14) Fassbender, K. et Watanabe, S. M. (2015). Early palliative care and its translation into oncology practice in Canada: barriers and challenges. *Annals of Palliative Medicine*, 4(3), 135-49.
- 15) Hanly, P., Pearce, A. et Sharp, L. (2014). The cost of premature cancer-related mortality:

- a review and assessment of the evidence. *Expert Review of Pharmacoeconomics & Outcomes Research*, 14(3), 355-77.
- 16) Howell, D. (2011). Palliative care research: urgent need for investment. *International Journal of Palliative Nursing*, 17(10), 471.
 - 17) Kanavos, P. et coll. (2010). The role of funding and policies on innovation in cancer drug development. *eCancer Medical Science*, 4. doi : 10.3332/ecancer.2010.164
 - 18) Katz, L. et coll. (2014). Using health care utilization and publication patterns to characterize the research portfolio and to plan future research investments. *PloS ONE*, 9(12), e114873.
 - 19) Leatherdale, S. T. (2015). An examination of the co-occurrence of modifiable risk factors associated with chronic disease among youth in the COMPASS study. *Cancer Causes & Control*, 26(4), 519-528.
 - 20) Lynch, M. E. et coll. (2009). Research funding for pain in Canada. *Pain Research and Management*, 14(2), 113-5.
 - 21) Matei, M. C. et coll. (2015). Cancer research investment: "Top-Down" versus bibliometric approach. *Revista medico-chirurgicala a Societatii de Medici si Naturalisti din Iasi*, 119(3), 828-34.
 - 22) Matei, M. C., Chirica, V. et Azoicai, D. (2015). A review of cancer research funding. *Social Research Reports*, 27, 3-25.
 - 23) Mauri, D. et coll. (2013). Cancer pain: Global awareness and guideline recommendation. *Forum of Clinical Oncology*, 4(3), 20-31.
 - 24) Meredith, A.J. et coll. (2015). A model to estimate frozen tissue collection targets in biobanks to support cancer research. *Biopreservation and Biobanking*, 13(5):356-62.
 - 25) Moretto, P. et coll. (2014). Kidney cancer survivorship survey of urologists and survivors: The gap in perceptions of care, but agreement on needs. *Canadian Urological Association Journal*, 8(5-6), 190-4.
 - 26) Patafio, F. M. et coll. (2015). Cancer mortality and published research output: Is there any relationship? 2015 ASCO Annual Meeting, *Journal of Clinical Oncology*, 33(suppl.), résumé 6596.
 - 27) Patafio, F. M. et coll. (2016). Research output and the public health burden of cancer: is there any relationship? *Current Oncology*, 23(2), 75-80.
 - 28) Riley, B. L. (2013). "The Magic Is in the Mix": Lessons From Research Capacity Building in the Canadian Tobacco Control Community, 2000–2010. *Canadian Journal of Public Health*, 104(2):e173-6.
 - 29) Sanson-Fisher, R. et coll. (2010). Quality of life research: is there a difference in output between the major cancer types? *European Journal of Cancer Care*, 19(6), 714-20.
 - 30) Sleeman, J. et Steeg, P. S. (2010). Cancer metastasis as a therapeutic target. *European Journal of Cancer*, 46(7), 1177-80.

Chapitres de livres

- 1) Clarke, J. N. (2016). *Health, Illness, and Medicine in Canada*. (7^e éd.). Toronto : Oxford University Press. [utilisation de la figure]
- 2) Hurlbert, M. et al. (2014). Landscape analysis of MBC research. Dans Metastatic Breast Cancer (MBC) Alliance, *Changing the Landscape for People Living with Metastatic Breast Cancer. Metastatic Breast Cancer Landscape Analysis: Research Report*. Repéré à http://www.mbcalliance.org/docs/MBCA_Full_Report_Landscape_Analysis.pdf
- 3) Kerner, J. (2010). Integrating science with service in cancer control: closing the gap between discovery and delivery. Dans J. M. Elwood et S. B. Sutcliffe (dir.), *Cancer Control*. Oxford : Oxford University Press.
- 4) Picco, G. (2017). *Cap in Hand: How Charities are Failing the People of Canada and the World*. Toronto : Civil Sector Press.
- 5) Stamatakis, K. A., Vinson, C. A. et Kerner, J. F. (2012). Dissemination and implementation research in community and public health settings. Dans R. C. Brownson, G. A. Colditz et E. K. Proctor (dir.), *Dissemination and Implementation Research in Health: Translating Science to Practice*. New York : Oxford University Press. (p. 359-80)
- 6) Gosain, R., Gill, A. S. et Miller, K. D. (2015). Cancer Care in Canada. In K.D. Miller et M.

Simon (dir.), *Global Perspectives on Cancer: Incidence, Care, and Experience*. Santa Barbara, CA : Praeger.

Articles de journal

- 1) Picard, A. (2007, 12 septembre). How cancer research dollars are spent. *The Globe and Mail*, A1.
- 2) Picard, A. (2008, 26 août). Five cents of every research dollar goes to cancer research – is it enough? *The Globe and Mail*, L4.
- 3) Picard, A (2009, 20 octobre). About 3% of cancer research focuses on childhood illness. *The Globe and Mail*, L6.

Rapports

- 1) Alliance canadienne pour la recherche sur le cancer du sein. (2009). *Cadre national de recherche sur le cancer du sein : une feuille de route pour la recherche*. Toronto : ACRC.
- 2) Collectif canadien pour la recherche sur le cancer du sein. (2016). *Surveillance du Cadre national de recherche sur le cancer du sein : un rapport produit par le Collectif canadien pour la recherche sur le cancer du sein*. Toronto : CCRCS.
- 3) Institut de recherche de la Société canadienne du cancer. (2015). *Rapport sur l'impact de la recherche en 2015*. Toronto : Institut de recherche de la Société canadienne du cancer. Repéré à https://issuu.com/canadiancancersociety/docs/ccsri_rir2015_en_jul2016_hires-fori?e=1256214/37135090
- 4) Instituts de recherche en santé du Canada. (2016). *Plan stratégique 2015-2020 de l'Institut du cancer : Miser sur l'innovation pour prévenir le cancer et mieux lutter contre la maladie dans l'intérêt de tous les Canadiens*. Ottawa : IRSC. Repéré à <http://www.cihr-irsc.gc.ca/f/49894.html>
- 5) Crooks, D. (2012). Neglected issues. *Report Card on Cancer in Canada, 2011-12*, 14, 48.
- 6) Hryniuk, W. et Gillespie, D. (2008). Cancer research funding, Part Two. Where do our research dollars go...still? *Report Card on Cancer in Canada, 2007*, 10, 11-5.

- 7) Cancer de la Prostate Canada. (2012). *Environmental Scan of Prostate Cancer Research in Canada, 2005-2011*. Toronto : Cancer de la Prostate Canada.

Articles en ligne

- 1) Silversides, A. et Sullivan, T. (2012). Cancer research: should investments reflect disease burden? Repéré à <http://healthydebate.ca/2012/10/topic/wa-it-times-access-to-care/cancer>

Présentations

- 1) Gotay, C. (2015). Trends in cancer research funding in Canada. Repéré à <http://cc-arcc.ca/wp-content/uploads/2015/01/Current-gotay.pdf>

Thèses

- 1) Cowling, A. E. (2014). *Yoga, Women, and Cancer: Experiences in a Specialized Yoga Program* (Maîtrise ès arts, Université York, Toronto).

Plan stratégique de l'ACRC

- 1) Joly, Y., Livingstone, A. et Dove, E. S. (2012). Au-delà de la commercialisation : Stratégies visant à maximiser l'impact économique et social de la recherche en génomique. Mémoire sur les orientations stratégiques n° 5. Génome Canada.
- 2) Matzke, E. A. M. et coll. (2012). Certification for Biobanks: The program developed by the Canadian Tumour Repository Network (CTRNet). *Biopreservation and Biobanking*, 10(5), 426-32.

Cadre de recherche sur la prévention

- 1) Ashbury, F. D. et coll. (2014). A vision for chronic disease prevention and intervention research: Report from a workshop. *Canadian Journal of Public Health*, 105(2), e150-3.

Rapport d'essais cliniques

- 1) Arts, K. E., Kato, D. et Dancey, J. (2015). Establishment of a baseline to measure academic clinical trial activity in Canada. 2015 ASCO Annual Meeting, *Journal of Clinical Oncology*, 33(suppl.), résumé 17547.
- 2) Bell, J. A. H. et Balneaves, L. G. (2015) Cancer patient decision making related to clinical trial participation: an integrative review with implications for patients' relational autonomy. *Supportive Care in Cancer*, 23(4), 1169-96.
- 3) Bell, J. A. H. et coll. (2016). Report on a Delphi process and workshop to improve accrual to cancer clinical trials. *Current Oncology*, 23(2), 125-30.
- 4) Dent, S. F. et Yurichuk, S. (2011). Should clinical trials be considered part of "standard of care"? *Report Card on Cancer in Canada, 2010-2011*, 13, 23-9.
- 5) Grant, J. et coll. (2016). Initiative to streamline clinical trials (ISCT): Guidance for academic investigators/sponsors. 2016 ASCO Quality Care Symposium, *Journal of Clinical Oncology*, 34(suppl. 7S), résumé 219.
- 6) Hay, A. E. et coll. (2016). Accrual of adolescents and young adults with cancer to clinical trials. *Current Oncology*, 23(2), e81-5.
- 7) Hébert, P. C. et Fergusson, D. A. (2010). Are we keeping research participants safe enough? *CMAJ*, 182(10), E428.
- 8) Lun, G. et coll. (2013). Use of a clinical assistant to screen patients with genitourinary cancer to encourage entry into clinical trials and use of supportive medicine: A pilot project at a Canadian cancer center. *Clinical Genitourinary Cancer*, 11(3), 342-5.
- 9) Meyer, R. M. et coll. (2011). Cooperative Group Cancer Clinical Trials: An NCIC Clinical Trials Group perspective. *Canadian Urological Association Journal*, 5(6), 379-81.
- 10) O'Leary, E. et coll. (2013). Data collection in cancer clinical trials: Too much of a good thing? *Clinical Trials*, 0, 1-9.
- 11) Price, A. et coll. (2016). Mind the gap in clinical trials: A participatory action analysis with citizen collaborators. *Journal of Evaluation in Clinical Practice*. doi : 10.1111/jep.12678.
- 12) Syme, R. et coll. (2015) Integrating personalized medicine in the Canadian environment: Efforts facilitating oncology clinical research. *Public Health Genomics*, 18, 372-80.
- 13) Thorne, S. et coll. (2013). Of Guinea pigs and gratitude: the difficult discourse of clinical trials from the cancer patient perspective. *European Journal of Cancer Care*, 22(5), 663-72.

L'ACRC elle-même

- 1) Knuttila, E. (2007). *Maximizing Patient Voices: Final Report*. Rapport produit pour le Réseau canadien de lutte contre le cancer.
- 2) Sullivan, R. et coll. (2013). New policies to address the global burden of childhood cancers. *The Lancet Oncology*, 14(3), e125-35.
- 3) Wranik, W.D. et coll. (2016). The evolution of the cancer formulary review in Canada: Can centralization improve the use of economic evaluation? *The International Journal of Health Planning and Management*. doi : 10.1002/hpm.2372